RxDoctor Payments Data

Kerry Biermann, MD

Family Medicine · Camas, WANPI 1437299088

Payments from drug & device makers

$1,878in general payments, 2019–2025

Across 110 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$395
  • Pfizer$195
  • Gilead$172
  • Merck$163
  • Amgen$148
  • Amarin Pharma, Inc.$121
  • plus $685 from 12 others

What the payments were for

  • Food & beverage$1,86099%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,878 in reported general payments places this provider in the 85th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$768
Medicare patients
42
Services billed
85

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol71$81,627
MounjaroTirzepatide54$58,515
XifaxanRifaximin16$53,545
TrulicityDulaglutide41$50,440
EliquisApixaban44$38,123
RybelsusSemaglutide11$27,628
Bydureon BciseExenatide Microspheres13$21,957
JardianceEmpagliflozin24$21,125
Repatha SureclickEvolocumab11$10,413
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,508
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$7,089
Atorvastatin Calcium592$5,517
NexlizetBempedoic Acid/Ezetimibe12$5,065
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$4,540
Potassium Chloride232$4,238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$74$108,95595 claims
AstraZenecaFarxiga$395$81,62771 claims
PfizerEliquis$195$38,12344 claims
Novo NordiskRybelsus$39$27,62811 claims
Boehringer IngelheimJardiance$54$21,12524 claims
GSKTrelegy Ellipta$62$9,50813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Camas

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →